{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:09:12Z","timestamp":1793372952393,"version":"4.5.0"},"reference-count":183,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jaccao.2022.04.002","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T13:58:42Z","timestamp":1655819922000},"page":"166-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Cardiovascular Disease in Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-6380","authenticated-orcid":false,"given":"Orly","family":"Leiva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Ravid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2022.04.002_bib1","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib2","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3390\/ijms20081839","article-title":"Blast transformation in myeloproliferative neoplasms: risk factors, biological findings, and targeted therapeutic options","volume":"20","author":"Iurlo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaccao.2022.04.002_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A\u00a0systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jaccao.2022.04.002_bib4","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1038\/bcj.2017.6","article-title":"The role of the extracellular matrix in primary myelofibrosis","volume":"7","author":"Leiva","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaccao.2022.04.002_bib5","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib6","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib7","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2022.04.002_bib8","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib11","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1253\/circj.CJ-18-0871","article-title":"Clonal hematopoiesis and its impact on cardiovascular disease","volume":"83","author":"Sano","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jaccao.2022.04.002_bib14","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1093\/eurheartj\/ehz907","article-title":"Somatic mosaicism: implications for the cardiovascular system","volume":"41","author":"Sano","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2022.04.002_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41569-019-0247-5","article-title":"Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease","volume":"17","author":"Jaiswal","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","article-title":"Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure","volume":"4","author":"Dorsheimer","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib17","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2021.02.028","article-title":"Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction","volume":"77","author":"Pascual-Figal","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib18","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/ehf2.13297","article-title":"Full spectrum of clonal haematopoiesis-driver mutations in chronic heart failure and their associations with mortality","volume":"8","author":"Kiefer","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jaccao.2022.04.002_bib19","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/eurheartj\/ehz591","article-title":"Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation","volume":"41","author":"Mas-Peiro","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2022.04.002_bib20","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41408-017-0035-6","article-title":"Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients","volume":"7","author":"Cerquozzi","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaccao.2022.04.002_bib21","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib22","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaccao.2022.04.002_bib24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib25","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib26","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-021-00470-y","article-title":"Mutations and thrombosis in essential thrombocythemia","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaccao.2022.04.002_bib28","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/leu.2011.82","article-title":"DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2022.04.002_bib29","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2022.04.002_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.19812","article-title":"Association of thrombosis with hypereosinophilic syndrome in patients with genetic alterations","volume":"4","author":"Leiva","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaccao.2022.04.002_bib31","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3390\/cancers12040934","article-title":"Thrombotic risk detection in patients with polycythemia vera: the predictive role of DNMT3A\/TET2\/ASXL1 mutations","volume":"12","author":"Segura-Diaz","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaccao.2022.04.002_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2022.04.002_bib33","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2022.04.002_bib34","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.3324\/haematol.2015.138958","article-title":"Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome","volume":"101","author":"Asp","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2022.04.002_bib35","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11239-017-1490-4","article-title":"Essential thrombocythemia presenting as acute coronary syndrome: case reports and literature review","volume":"44","author":"Xiong","year":"2017","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jaccao.2022.04.002_bib37","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2169\/internalmedicine.2083-18","article-title":"In-stent massive thrombi formation during primary percutaneous coronary intervention in a patient with acute myocardial infarction complicated with essential thrombocythemia","volume":"58","author":"Shoji","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2796.1998.00314.x","article-title":"Acute coronary disease in essential thrombocythemia and polycythemia vera","volume":"244","author":"Rossi","year":"1998","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3760\/cma.j.issn.0366-6999.20131855","article-title":"Acute ST-elevation myocardial infarction in a patient with polycythemia vera","volume":"127","author":"Zhang","year":"2014","journal-title":"Chin Med J (Engl)"},{"issue":"3-4","key":"10.1016\/j.jaccao.2022.04.002_bib40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bcmd.2012.06.004","article-title":"Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications","volume":"49","author":"Malak","year":"2012","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jaccao.2022.04.002_bib41","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"issue":"2-3","key":"10.1016\/j.jaccao.2022.04.002_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0049-3848(03)00290-1","article-title":"Myeloproliferative syndromes and the associated risk of coronary artery disease","volume":"110","author":"Ganti","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.jaccao.2022.04.002_bib43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.leu.2404048","article-title":"Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution","volume":"20","author":"Cervantes","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2022.04.002_bib44","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.canep.2015.01.014","article-title":"Risk of Wernicke\u2019s encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm","volume":"39","author":"Wu","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib45","doi-asserted-by":"crossref","first-page":"10711","DOI":"10.1111\/jcmm.17007","article-title":"PKM2 promotes angiotensin-II-induced cardiac remodelling by activating TGF-beta\/Smad2\/3 and Jak2\/Stat3 pathways through oxidative stress","volume":"25","author":"Zhang","year":"2021","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCRESAHA.117.311045","article-title":"EphrinB2 regulates cardiac fibrosis through modulating the interaction of Stat3 and TGF-beta\/Smad3 signaling","volume":"121","author":"Su","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2022.04.002_bib47","first-page":"684","article-title":"JAK2 (V617F)-mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure","volume":"4","author":"Sano","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jaccao.2022.04.002_bib48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacc.2016.05.043","article-title":"High-output heart failure: a 15-year experience","volume":"68","author":"Reddy","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib49","first-page":"245","article-title":"Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders","volume":"89","author":"Garypidou","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2022.04.002_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejim.2019.08.004","article-title":"Pulmonary hypertension in patients with myeloproliferative neoplasms: a large cohort of 183 patients","volume":"68","author":"Venton","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ejh.13197","article-title":"Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms","volume":"102","author":"Brabrand","year":"2019","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.jaccao.2022.04.002_bib52","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood-2021-149799","article-title":"Pulmonary hypertension is associated with poor outcomes in patients with myeloproliferative neoplasms and cardiovascular disease","volume":"138","author":"Leiva","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib53","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.echo.2019.07.010","article-title":"Incremental utility of right ventricular dysfunction in patients with myeloproliferative neoplasm-associated pulmonary hypertension","volume":"32","author":"Kim","year":"2019","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jaccao.2022.04.002_bib54","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.healun.2014.09.009","article-title":"Impaired right ventricular-pulmonary vascular function in myeloproliferative neoplasms","volume":"34","author":"Roach","year":"2015","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jaccao.2022.04.002_bib55","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2353\/ajpath.2008.070705","article-title":"Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension","volume":"172","author":"Asosingh","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib56","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1182\/blood-2010-09-306357","article-title":"Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities","volume":"117","author":"Farha","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib57","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/2045893217702064","article-title":"Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series","volume":"7","author":"Singh","year":"2017","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jaccao.2022.04.002_bib58","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.2169\/internalmedicine.8629-16","article-title":"Pulmonary hypertension associated with pulmonary veno-occlusive disease in patients with polycythemia vera","volume":"56","author":"Tachibana","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib59","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.3390\/ijms21093339","article-title":"Myeloproliferative diseases as possible risk factor for development of chronic thromboembolic pulmonary hypertension\u2014a genetic study","volume":"21","author":"Eichstaedt","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaccao.2022.04.002_bib60","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2016.85","article-title":"High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists","volume":"30","author":"De Stefano","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2022.04.002_bib61","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1161\/CIRCRESAHA.118.313283","article-title":"Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 (V617F) mice","volume":"123","author":"Wang","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2022.04.002_bib62","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41586-021-03341-5","article-title":"The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis","volume":"592","author":"Fidler","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jaccao.2022.04.002_bib63","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1161\/CIRCRESAHA.118.314074","article-title":"Jak-ing up the plaque\u2019s lipid core\u2026and even more","volume":"123","author":"Libby","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2022.04.002_bib64","first-page":"481","article-title":"Internal bleeding: is intraplaque hemorrhage a decoration or a driver?","volume":"3","author":"Michel","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jaccao.2022.04.002_bib65","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s42003-022-03078-5","article-title":"Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux","volume":"5","author":"Dotan","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib66","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2022.04.002_bib67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosis.2020.01.001","article-title":"Progression of coronary calcium burden and carotid stiffness in patients with essential thrombocythemia associated with JAK2 V617F mutation","volume":"296","author":"Anzic Drofenik","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jaccao.2022.04.002_bib68","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.jcin.2018.02.025","article-title":"Peripheral artery disease associated with myeloproliferative disorders","volume":"11","author":"Nakagawa","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jaccao.2022.04.002_bib69","author":"Zekavat"},{"key":"10.1016\/j.jaccao.2022.04.002_bib70","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1055\/s-0039-1692204","article-title":"Emerging factors implicated in fibrotic organ-associated thrombosis: the case of two organs","volume":"3","author":"Leiva","year":"2019","journal-title":"TH Open"},{"key":"10.1016\/j.jaccao.2022.04.002_bib71","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaccao.2022.04.002_bib72","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2022.04.002_bib73","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/leu.2013.207","article-title":"Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis","volume":"27","author":"Barbui","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2022.04.002_bib74","doi-asserted-by":"crossref","unstructured":"Krecak I, Holik H, Moric Peric M, et\u00a0al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in polycythemia vera. Int J Lab Hematol. Published online December 30, 2021.","DOI":"10.1111\/ijlh.13786"},{"key":"10.1016\/j.jaccao.2022.04.002_bib75","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaut.2017.06.010","article-title":"Inflammation and myeloproliferative neoplasms","volume":"85","author":"Lussana","year":"2017","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaccao.2022.04.002_bib76","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaccao.2022.04.002_bib77","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib78","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib79","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis","volume":"87","author":"Vaidya","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib80","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib81","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jaccao.2022.04.002_bib82","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib83","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1182\/blood-2011-01-330050","article-title":"Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells","volume":"118","author":"Yahata","year":"2011","journal-title":"Blood"},{"issue":"16-17","key":"10.1016\/j.jaccao.2022.04.002_bib84","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.clinbiochem.2012.07.100","article-title":"Changes in advanced oxidation protein products, advanced glycation end products, and s-nitrosylated proteins, in patients affected by polycythemia vera and essential thrombocythemia","volume":"45","author":"Musolino","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jaccao.2022.04.002_bib85","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.exphem.2010.07.005","article-title":"Oxidative stress is increased in primary and post-polycythemia vera myelofibrosis","volume":"38","author":"Vener","year":"2010","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib86","first-page":"2860","article-title":"Increased oxidative stress in patients with essential thrombocythemia","volume":"17","author":"Durmus","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jaccao.2022.04.002_bib87","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/antiox11010113","article-title":"The response to oxidative damage correlates with driver mutations and clinical outcome in patients with myelofibrosis","volume":"11","author":"Genovese","year":"2022","journal-title":"Antioxidants (Basel)"},{"issue":"3A","key":"10.1016\/j.jaccao.2022.04.002_bib88","doi-asserted-by":"crossref","first-page":"7A","DOI":"10.1016\/S0002-9149(02)03144-2","article-title":"Role of oxidative stress in atherosclerosis","volume":"91","author":"Harrison","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib89","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1365-2796.2004.01373.x","article-title":"Oxidative stress and its association with coronary artery disease and different atherogenic risk factors","volume":"256","author":"Vassalle","year":"2004","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib90","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/10715760500539154","article-title":"Plasma 8-iso-prostaglandin F2alpha, a marker of oxidative stress, is increased in patients with acute myocardial infarction","volume":"40","author":"Elesber","year":"2006","journal-title":"Free Radic Res"},{"key":"10.1016\/j.jaccao.2022.04.002_bib91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.ATV.0000150649.39934.13","article-title":"Oxidative stress and vascular disease","volume":"25","author":"Madamanchi","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib92","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib93","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib94","article-title":"Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: observations from the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib\u2013Thrombolysis In Myocardial Infarction 52) Trial","volume":"6","author":"Fanola","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2022.04.002_bib95","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Kaptoge","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib96","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib97","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib98","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib99","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10555-006-9004-4","article-title":"The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions","volume":"25","author":"Apte","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jaccao.2022.04.002_bib100","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/cvr\/cvz058","article-title":"Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology","volume":"115","author":"Libby","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2022.04.002_bib101","doi-asserted-by":"crossref","first-page":"a028662","DOI":"10.1101\/cshperspect.a028662","article-title":"Cancer inflammation and cytokines","volume":"10","author":"Galdiero","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib102","doi-asserted-by":"crossref","first-page":"11100","DOI":"10.1111\/jcmm.15526","article-title":"Transforming growth factor beta-mediated micromechanics modulates disease progression in primary myelofibrosis","volume":"24","author":"Teodorescu","year":"2020","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib103","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41375-020-0880-3","article-title":"Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice","volume":"35","author":"Ozono","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2022.04.002_bib104","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM200005043421807","article-title":"Role of transforming growth factor beta in human disease","volume":"342","author":"Blobe","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib105","first-page":"4222","article-title":"TGFbeta1 upregulates the expression of lncRNAATB to promote atherosclerosis","volume":"19","author":"Yu","year":"2019","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.jaccao.2022.04.002_bib106","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1172\/JCI82719","article-title":"Endothelial-to-mesenchymal transition drives atherosclerosis progression","volume":"125","author":"Chen","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaccao.2022.04.002_bib107","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.atherosclerosis.2014.10.021","article-title":"Platelet expression of transforming growth factor beta 1 is enhanced and associated with cardiovascular prognosis in patients with acute coronary syndrome","volume":"237","author":"Rath","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jaccao.2022.04.002_bib108","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.7754\/Clin.Lab.2013.130337","article-title":"Transforming growth factor beta 1 as a risk factor for cardiovascular diseases in end-stage renal disease patients treated with peritoneal dialysis","volume":"60","author":"Janda","year":"2014","journal-title":"Clin Lab"},{"key":"10.1016\/j.jaccao.2022.04.002_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2018.02.006","article-title":"The morphological and molecular mechanisms of epithelial\/endothelial-to-mesenchymal transition and its involvement in atherosclerosis","volume":"106","author":"Wesseling","year":"2018","journal-title":"Vascul Pharmacol"},{"issue":"19-20","key":"10.1016\/j.jaccao.2022.04.002_bib110","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1007\/s00018-006-6149-9","article-title":"Lysyl oxidase: an oxidative enzyme and effector of cell function","volume":"63","author":"Lucero","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jaccao.2022.04.002_bib111","doi-asserted-by":"crossref","first-page":"27630","DOI":"10.1074\/jbc.M111.243113","article-title":"Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase","volume":"286","author":"Eliades","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaccao.2022.04.002_bib112","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ajh.23409","article-title":"The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms","volume":"88","author":"Tadmor","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib113","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2017-04-777417","article-title":"Upregulation of lysyl oxidase and adhesion to collagen of human megakaryocytes and platelets in primary myelofibrosis","volume":"130","author":"Abbonante","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib114","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1182\/blood-2015-02-629667","article-title":"Lysyl oxidase is associated with increased thrombosis and platelet reactivity","volume":"127","author":"Matsuura","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib115","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.25008","article-title":"The role of extracellular matrix stiffness in megakaryocyte and platelet development and function","volume":"93","author":"Leiva","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib116","doi-asserted-by":"crossref","first-page":"24103","DOI":"10.1074\/jbc.M709897200","article-title":"Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascular smooth muscle cells","volume":"283","author":"Lucero","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaccao.2022.04.002_bib117","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12185-019-02751-6","article-title":"Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice","volume":"110","author":"Leiva","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib118","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/cvr\/cvn102","article-title":"Regulation of lysyl oxidase in vascular cells: lysyl oxidase as a new player in cardiovascular diseases","volume":"79","author":"Rodriguez","year":"2008","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2022.04.002_bib119","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1161\/01.ATV.0000064372.78561.A5","article-title":"Elastogenesis in human arterial disease: a role for macrophages in disordered elastin synthesis","volume":"23","author":"Krettek","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib120","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1161\/01.ATV.0000033818.21748.99","article-title":"Low density lipoproteins downregulate lysyl oxidase in vascular endothelial cells and the arterial wall","volume":"22","author":"Rodriguez","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib121","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/01.ATV.1.4.287","article-title":"Changes in aortic lysyl oxidase activity in diet-induced atherosclerosis in the rabbit","volume":"1","author":"Kagan","year":"1981","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.jaccao.2022.04.002_bib122","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/joim.12228","article-title":"The collagen cross-linking enzyme lysyl oxidase is associated with the healing of human atherosclerotic lesions","volume":"276","author":"Ovchinnikova","year":"2014","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib123","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jvs.2004.02.028","article-title":"Lysyl oxidase expression in a rat model of arterial balloon injury","volume":"40","author":"Nuthakki","year":"2004","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jaccao.2022.04.002_bib124","doi-asserted-by":"crossref","first-page":"H2228","DOI":"10.1152\/ajpheart.00410.2005","article-title":"Collagen and elastin cross-linking: a mechanism of constrictive remodeling after arterial injury","volume":"289","author":"Brasselet","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/cvr\/cvv214","article-title":"Matrix cross-linking lysyl oxidases are induced in response to myocardial infarction and promote cardiac dysfunction","volume":"109","author":"Gonzalez-Santamaria","year":"2016","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2022.04.002_bib126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064986","article-title":"Left and right ventricle late remodeling following myocardial infarction in rats","volume":"8","author":"Stefanon","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jaccao.2022.04.002_bib127","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/jcmm.14074","article-title":"The lysyl oxidase like 2\/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis","volume":"23","author":"Schilter","year":"2019","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib128","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/09537104.2019.1665640","article-title":"Percutaneous coronary intervention in patients with essential thrombocythemia: case reports and literature review","volume":"31","author":"Zheng","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.jaccao.2022.04.002_bib129","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/leu.2014.343","article-title":"CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis","volume":"29","author":"Finazzi","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2022.04.002_bib130","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis","volume":"3","author":"Carobbio","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2022.04.002_bib131","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJMoa012295","article-title":"Widespread coronary inflammation in unstable angina","volume":"347","author":"Buffon","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib132","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2022.04.002_bib133","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/eurheartj\/ehv044","article-title":"TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion","volume":"36","author":"Quillard","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2022.04.002_bib134","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood-2013-10-463646","article-title":"Thrombosis: tangled up in NETs","volume":"123","author":"Martinod","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib135","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1080\/15384101.2019.1662678","article-title":"Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-\u03baB signaling in macrophages","volume":"18","author":"An","year":"2019","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jaccao.2022.04.002_bib136","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1161\/CIRCRESAHA.120.315931","article-title":"Neutrophil extracellular traps participate in cardiovascular diseases: recent experimental and clinical insights","volume":"126","author":"Doring","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2022.04.002_bib137","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","article-title":"Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera","volume":"96","author":"Falanga","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib138","doi-asserted-by":"crossref","first-page":"38738","DOI":"10.1038\/srep38738","article-title":"Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms","volume":"6","author":"Marin Oyarzun","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaccao.2022.04.002_bib139","doi-asserted-by":"crossref","first-page":"13076","DOI":"10.1073\/pnas.1200419109","article-title":"Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis","volume":"109","author":"Demers","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaccao.2022.04.002_bib140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib141","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms: a contemporary review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib142","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00277-007-0386-3","article-title":"Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis","volume":"87","author":"Alvarez-Larran","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib143","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2022.04.002_bib144","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib145","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/blood-2009-08-236679","article-title":"The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy","volume":"115","author":"Dragani","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib146","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1161\/ATVBAHA.120.314760","article-title":"Platelet dysfunction and thrombosis in JAK2(V617F)-mutated primary myelofibrotic mice","volume":"40","author":"Matsuura","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib147","first-page":"894","article-title":"Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders","volume":"103","author":"Malpass","year":"1984","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib148","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12185-013-1475-9","article-title":"JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients","volume":"99","author":"Coucelo","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib149","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/cvr\/cvz156","article-title":"Red blood cell dysfunction: a new player in cardiovascular disease","volume":"115","author":"Pernow","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2022.04.002_bib150","doi-asserted-by":"crossref","first-page":"102368","DOI":"10.1016\/j.bcmd.2019.102368","article-title":"High red blood cell distribution width might predict thrombosis in essential thrombocythemia and polycythemia vera","volume":"80","author":"Krecak","year":"2020","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jaccao.2022.04.002_bib151","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000445247","article-title":"The degree of anisocytosis predicts survival in patients with primary myelofibrosis","volume":"136","author":"Lucijanic","year":"2016","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib152","first-page":"37","article-title":"High red blood cell distribution width is closely associated with risk of carotid artery atherosclerosis in patients with hypertension","volume":"15","author":"Wen","year":"2010","journal-title":"Exp Clin Cardiol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib153","first-page":"E402","article-title":"Red blood cell distribution width and cardiovascular diseases","volume":"7","author":"Danese","year":"2015","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jaccao.2022.04.002_bib154","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib155","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1172\/JCI124566","article-title":"Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm","volume":"130","author":"Poisson","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaccao.2022.04.002_bib156","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/ham.2017.0123","article-title":"Excessive erythrocytosis and cardiovascular risk in andean highlanders","volume":"19","author":"Corante","year":"2018","journal-title":"High Alt Med Biol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib157","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/svn-2018-000149","article-title":"Association between admission haematocrit and mortality among men with acute ischaemic stroke","volume":"3","author":"Sico","year":"2018","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib158","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.4161\/cbt.6.9.4568","article-title":"Bone marrow renin-angiotensin system expression in polycythemia vera and essential thrombocythemia depends on JAK2 mutational status","volume":"6","author":"Vrsalovic","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jaccao.2022.04.002_bib159","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-11-752600","article-title":"ACE inhibitors and cytoreductive therapy in polycythemia vera","volume":"129","author":"Barbui","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib160","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1111\/jcmm.13710","article-title":"Captopril mitigates splenomegaly and myelofibrosis in the Gata1(low) murine model of myelofibrosis","volume":"22","author":"Corey","year":"2018","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib161","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0034-1370794","article-title":"Thrombosis in myeloproliferative neoplasms","volume":"40","author":"Falanga","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jaccao.2022.04.002_bib162","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib163","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larran","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib164","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.trsl.2018.05.009","article-title":"Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count","volume":"200","author":"Gremmel","year":"2018","journal-title":"Transl Res"},{"key":"10.1016\/j.jaccao.2022.04.002_bib165","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A\u00a0randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"Rocca","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib166","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaccao.2022.04.002_bib167","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood.V68.6.1213.1213","article-title":"Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome","volume":"68","author":"Budde","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib168","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-018-0048-9","article-title":"Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaccao.2022.04.002_bib169","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-018-0101-8","article-title":"Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaccao.2022.04.002_bib170","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/bloodadvances.2020003628","article-title":"A\u00a0systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms","volume":"5","author":"Hamulyak","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.jaccao.2022.04.002_bib171","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1182\/blood-2021-148941","article-title":"High incidence of bleeding found with direct oral anticoagulant use in myeloproliferative neoplasm patients","volume":"138","author":"How","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib172","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3324\/haematol.2021.279032","article-title":"Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study","volume":"107","author":"Zwicker","year":"2022","journal-title":"Haematologica"},{"issue":"suppl_1","key":"10.1016\/j.jaccao.2022.04.002_bib173","doi-asserted-by":"crossref","first-page":"A10074","DOI":"10.1161\/circ.144.suppl_1.10074","article-title":"Abstract 10074: cardiovascular outcomes in patients with concurrent atrial fibrillation and myeloproliferative neoplasms","volume":"144","author":"Leiva","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.04.002_bib174","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2022.04.002_bib175","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-driven clonal hematopoiesis and response to canakinumab","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib176","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1093\/eurheartj\/ehab447","article-title":"The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms","volume":"42","author":"Baldini","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2022.04.002_bib177","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A\u00a0pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2022.04.002_bib178","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2022.04.002_bib179","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.04.002_bib180","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.04.002_bib181","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/MBC.0000000000000446","article-title":"The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis","volume":"27","author":"Samuelson","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jaccao.2022.04.002_bib182","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.3324\/haematol.2015.128918","article-title":"The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms","volume":"100","author":"Keohane","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2022.04.002_bib183","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322002204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322002204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:55:08Z","timestamp":1762973708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087322002204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":183,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2666087322002204"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.04.002","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Disease in Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}